Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
Upon completion of the activity, participants should be able to:
1. Explain to patients and peers the scientific rationale and empirical data with biosimilars that make them as safe and effective as their biologic originators for rheumatologic conditions
2. Explain the circumstances under which it is appropriate to initiate or switch a patient with rheumatoid arthritis to a biosimilar
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.